---
title: "medical README part1 16"
description: "Auto-generated from filename."
pubDate: 2026-03-24
---

# 🏥 Medical Focus --- Day28 Compliance Mapping 🩺

🎯 **Objective** 🎯 \-\-\-\-\-\-\-\--Apply this day in **Medical**
context with explicit safety, compliance, and evidence expectations. The
goal is to ensure that all hardware-in-the-loop (HIL) systems meet the
stringent requirements of medical safety and efficacy. This is crucial
for patient outcomes and regulatory adherence.

🔧 **Phase Context** 🔧 \-\-\-\-\-\-\-\-\-\-\-\--Phase: **HIL** Primary
focus: **hardware-integrated timing and interface confidence**. Section
focus: **medical verification workflow**.

📜 **Domain Constraints** 📜 \-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--
Compliance baseline: **IEC 62304 + ISO 14971 + IEC 60601 context**. -
Key hazard profile: - Incorrect dosage delivery 🟡 - Missed alarm 🔴 -
Unsafe therapy continuation 🔴 - Interface landscape: device buses,
sensor links, alarm/event channels.

🧪 **Domain-Specific Examples** 🧪
\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-- **Nominal** 🟢:
Therapy control with validated sensor feedback. - **Boundary** 🟡:
Near-threshold dosing and alarm escalation timing. - **Fault** 🔴:
Sensor spike/dropout and actuator command rejection path.

🔍 **Patterns** 🔍 \-\-\-\-\-\-\-\-- Derive acceptance thresholds from
hazard-linked requirements. - Keep interface timing contracts explicit
and reviewable. - Compare nominal and stressed traces against the same
baseline.

🚫 **Anti-Patterns** 🚫 \-\-\-\-\-\-\-\-\-\-\-\-\-- Generic test claims
without domain hazard mapping. - Pass/fail decisions without
quantitative thresholds. - Evidence summaries without raw artifact
references.

⚠️ **Pitfalls** ⚠️ \-\-\-\-\-\-\-\-- Hidden assumptions in environment
or calibration setup. - Missing negative-path scenarios for
high-criticality behavior. - Incomplete traceability from requirement to
verdict.

🌟 **Best Practices** 🌟 \-\-\-\-\-\-\-\-\-\-\-\-\-\-- Tag every
artifact with domain requirement IDs. - Capture timing + functional
evidence in the same run package. - Record residual risk and ownership
before closure.

🧠 **Heuristics** 🧠 \-\-\-\-\-\-\-\-\-\-- If a domain hazard is
untested, confidence is provisional. - If rerun differs unexpectedly,
investigate determinism first. - If evidence is indirect, reduce verdict
confidence level.

✅ **Checklist** ✅ \-\-\-\-\-\-\-\--.. list-table:: Pre-Review
Checklist :widths: 1 1 :header-rows: 1

> -   -   Item
>     -   Status
>
> -   -   Domain hazard coverage is explicit.
>     -   ☐
>
> -   -   Compliance references are mapped to evidence.
>     -   ☐
>
> -   -   Nominal/boundary/fault results are all documented.
>     -   ☐
>
> -   -   Residual risks and next actions are assigned.
>     -   ☐

📊 **GIVEN / WHEN / THEN Scenarios** 📊
\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--**Nominal
Scenario** 🟢 GIVEN a validated sensor feedback system, WHEN therapy
control is activated, THEN the system delivers the correct dosage
without alarms.

**Boundary Scenario** 🟡 GIVEN a near-threshold dosing condition, WHEN
the alarm escalation timing is triggered, THEN the system must alert the
operator within the defined time frame.

**Fault Scenario** 🔴 GIVEN a sensor spike/dropout event, WHEN the
actuator command is issued, THEN the system must reject the command and
trigger a fault alarm.

::: note
::: title
Note
:::

Ensure that all scenarios are tested and documented to maintain
compliance with IEC 62304 and ISO 14971.
:::

::: important
::: title
Important
:::

Always prioritize safety-critical paths in testing to mitigate risks
associated with high-hazard profiles.
:::

::: warning
